This four-episode podcast is designed to identify and analyze the educational needs and practice gaps that exist among healthcare practitioners who are involved in the diagnosis and management of patients with Alzheimer’s disease. This program will educate participants on providing a timely diagnosis, referral, and appropriate treatment. We will hear from a primary care physician, a neurologist, a geriatrician, and a geriatric psychiatrist on the importance of multidisciplinary care and shared decisions in the diagnosis and treatment of mild cognitive impairment (MCI) due to Alzheimer’s disease (AD).

RELEASED DATE: April 25, 2025
EXPIRATION DATE: May 16, 2026

In this enduring grand rounds program, we will provide instruction on screening, diagnosing, and staging of mild cognitive impairment and Alzheimer's disease. The lecture and case-based scenarios will educate on the appropriate use of disease-modifying therapy, assessing and managing adverse events associated with these therapies, and implementing tools to solve issues with access to therapy. Finally, the faculty will discuss shared decision making and multidisciplinary teams as essential elements for successful care of these patients.

RELEASED DATE: May 15, 2025
EXPIRATION DATE: May 15, 2026

This educational activity is designed to provide participants with important clinical information on screening, diagnosing, and staging mild cognitive impairment and Alzheimer's disease. Through the use of high-quality images and graphics, along with detailed slide-based presentation, our faculty will address clinical practice recommendations informing the use of disease-modifying therapy for Alzheimer's disease, and provide tools on how to best assess and manage potential adverse events associated with these agents. This educational program will help clinicians to apply best practices for shared decision making with patients, including discussion of treatment benefits, risks, and therapy expectations.

RELEASED DATE: May 20, 2025
EXPIRATION DATE: May 20, 2026

This enduring activity is designed to offer multidisciplinary expert perspectives on the early identification of mild cognitive impairment (MCI) associated with Alzheimer’s disease (AD), appropriate patient referral, as well as treatment individualization for AD, focusing on disease-modifying therapies and their application to patient care. Through expert pearls and interactive case-based discussions, this series will highlight key considerations across both primary and specialty care in order to optimize multidisciplinary collaboration and patient outcomes throughout the care continuum.

RELEASED DATE: June 01, 2025
EXPIRATION DATE: June 01, 2026

This case-based educational activity is designed to enable providers who manage patients with Alzheimer's disease (AD) to more effectively diagnose mild cognitive impairment (MCI) due to AD. Expert faculty will review updated criteria for screening, diagnosis, and staging; outline best practices for patient evaluation, including medical history and cognitive and diagnostic screening tools; and provide guidance on when to refer patients to specialists. Employing an interactive case-based learning platform, our faculty will assist learners with developing strategies to improve multidisciplinary and clinician/patient communication for shared decision making.

RELEASED DATE: June 30, 2025
EXPIRATION DATE: June 30, 2026

This program has been developed to educate health care practitioners who care for patients with Alzheimer’s disease on the importance of early diagnosis of mild cognitive impairment (MCI) due to Alzheimer’s disease, timely specialist referral, and effective treatment and monitoring of patients receiving anti-amyloid therapies. It highlights the importance of a multidisciplinary, shared decision-making approach to optimize care management. This Day in the Life docuseries provides unique insights into the patient’s journey from diagnosis to treatment and the physician’s perspective on the clinical strategies for managing disease symptoms.

RELEASED DATE: July 25, 2025
EXPIRATION DATE: July 25, 2026

This enduring activity is designed to help clinicians to improve their care of patients with Alzheimer's Disease through integration of appropriate screening, diagnosis, and staging pathways for MCI and AD. Clinicians will learn how to integrate current evidence-based guidelines to inform selection of disease-modifying therapy for AD patients and improve their ability to monitor for and manage potential adverse events associated with these therapies. Participants will also learn about the use of shared decision-making (SDM) approaches with patients and caregivers to facilitate diagnosis and optimize care plans.

RELEASED DATE: May 30, 2025
EXPIRATION DATE: May 30, 2026

This enduring activity is designed to provide learners with important clinical information on screening, diagnosing, and staging mild cognitive impairment and Alzheimer’s disease. The content will address clinical practice recommendations informing the use of disease-modifying therapy for Alzheimer’s disease, and provide tools on how to assess and manage potential adverse events associated with these agents. Finally, this educational program will help clinicians apply best practices for shared decision making.

RELEASED DATE: March 10, 2025
EXPIRATION DATE: March 10, 2026

The goal of this program is to provide practicing clinicians recommendations informing the use of disease-modifying therapies (DMTs) for Alzheimer's disease (AD) and the identification of those who qualify for treatment based on available clinical data, as well as information on how to manage potential adverse events associated with DMTs for AD using a multidisciplinary approach.

RELEASED DATE: May 30, 2025
EXPIRATION DATE: May 30, 2026

This educational initiative is designed for pharmacists in the United States and globally who are involved in the care of patients with early symptomatic Alzheimer's disease (MCI due to AD, or mild dementia due to AD). It uses a multi-component platform – the DETECT Initiative – to increase learner ability to: review evolving clinical data informing the use of anti-amyloid therapeutics (ATTs) in the care of patients with AD, including mechanisms, efficacy, safety, and dosing and administration best practices; apply best practices for individualized patient counseling to ensure adequate monitoring and management in the provision of ATTs; design guideline-informed evidence-based protocols for preparation, dosing, and scheduling of ATTs in the clinical settings; and facilitate the management of financial and reimbursement issues for patients receiving ATTs.

RELEASED DATE: March 12, 2025
EXPIRATION DATE: March 12, 2026